Regions – Page 43 – pharmaceutical daily

December 15, 2021 Off

Sartorius and HOF Sonderanlagenbau Partnership Creates Streamlined Offering of Freeze-Thaw Solutions for Biological Products

Sartoriusand HOF Sonderanlagenbau, announced a partnership today to integrate two HOF horizontal plate freeze-thaw units into Sartorius’ portfolio offering customers a full suite of compatible freeze-thaw equipment and consumables. This partnership will enable faster and easier implementation of robust frozen drug substance management platforms through improved validation and purchase support from a single supplier.

December 13, 2021 Off

Pfizer buys Arena Pharmaceuticals ($6.7 billion)

By Dino Mustafić

Pfizer will acquire Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases, Pfizer said in a press release Monday.

December 13, 2021 Off

Dupixent significantly improved disease severity in a trial that met all endpoints

By Dino Mustafić

Positive Phase 3 results show adding Dupixent (dupilumab) to standard-of-care topical corticosteroids (TCS) significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.

December 13, 2021 Off

Acacia Pharma completes its post-approval requirement clinical trial testing Barhemsys in individuals with severe renal impairment

By Dino Mustafić

Acacia Pharma Group has completed its post-approval requirement clinical trial investigating the effects of BARHEMSYS® (amisulpride injection) in individuals with severe renal impairment.

December 13, 2021 Off

Study shows positive results for Roche’s Hemlibra in people with moderate or mild haemophilia A

By Dino Mustafić

Roche interim analysis of the phase III HAVEN 6 study, which show Hemlibra (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.

December 13, 2021 Off

Roche launches system to advance sequencing technologies

By Dino Mustafić

Roche has launched the AVENIO Edge System, a core component of Roche’s strategy to advance sequencing technologies. Built on best-in-class foundational capabilities to deliver a fully-automated, integrated sequencing solution.

December 10, 2021 Off

Moderna’s Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains

By Dino Mustafić

Moderna today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010, as it successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.

December 10, 2021 Off

Vifor Pharma and Angion phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury misses goal

By BusinessWire

Vifor Pharma and Angion Biomedica’s exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).

December 10, 2021 Off

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18y and above, across six countries.

December 8, 2021 Off

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus

By Dino Mustafić

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus.